III. Calcium channel blockers, angiotensin II receptor blockers and compound preparations are the major varieties on the Chinese market, with compound preparations growing fast
According to data of the PDB of China National Pharmaceutical Industry Information Center, calcium channel blockers, angiotensin II receptor blockers (ARBs) and compound preparations accounted for more than half of the market shares among the antihypertensive drugs in China in 2015, separately accounting for 35%, 26% and 16%.
Chart 16 Sales proportions of each subcategory of antihypertensive drugs in China in 2015

|
钙拮抗剂 血管紧张素II受体拮抗剂(ARB) 复方降压药 β-受体阻滞剂 血管紧张素转换酶抑制剂(ACEI) 利尿类 |
Calcium antagonists Angiotensin II receptor blockers (ARBs) Compound antihypertensive drugs β-receptor blockers Angiotensin converting enzyme inhibitors (ACEIs) Diuretics |
3.1 Calcium channel blockers
Sales growth of the calcium channel blockers tended to be stable in sample hospitals and slightly declined in 2015, seen from data of PDB.
Chart 17 Sales situation of calcium antagonists in key hospitals in 2011-2015

Sales proportion of the Chinese antihypertensive drug calcium antagonists was 70.1% in hospital terminal according to data of Sinohealth CMH. In hospital terminal, 94.3% calcium antagonists were non-injection preparation, with the accumulative market shares of the top 10 products by sales of 74.9%, showing a high market concentration. The hospital market was dominated by foreign enterprises.
Chart 18 Top 10 by market sales of non-injection calcium antagonists in hospital terminal in 2015










(All Rights Reserved)